Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John K. Hsiao

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
JAMA|February 22, 2022
Sublingual Dexmedetomidine as a Potential New Treatment for AgitationJohn K Hsiao
JAMA|June 22, 2026
Stopping Alzheimer Disease: 50 Years of ProgressJohn K Hsiao
Psychiatric Services (Washington, D.C.)|January 10, 2006
Interpreting the results of the CATIE studyJeffrey A Lieberman, John K Hsiao
Convulsive Therapy|January 1, 1987
ECT and Neurological DisordersJohn K. Hsiao, John A. Messenheimer, Dwight L. Evans
Convulsive Therapy|January 1, 1988
Disparate Biochemical Actions of Electroconvulsive Therapy and Antidepressant DrugsMatthew V. Rudorfer, Emile D. Risby, John K. Hsiao, et al.
The American Journal of Psychiatry|March 4, 2006
Barriers to employment for people with schizophreniaRobert Rosenheck, Douglas Leslie, Richard Keefe, et al.
Psychiatric Services (Washington, D.C.)|May 3, 2008
What CATIE found: results from the schizophrenia trialMarvin S Swartz, T Scott Stroup, Joseph P McEvoy, et al.
Schizophrenia Research|November 26, 2008
Results of phase 3 of the CATIE schizophrenia trialT Scott Stroup, Jeffrey A Lieberman, Joseph P McEvoy, et al.
The American Journal of Psychiatry|June 4, 2008
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trialDavid L Sultzer, Sonia M Davis, Pierre N Tariot, et al.
Biological Psychiatry|July 31, 2009
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness studyJonathan M Meyer, Joseph P McEvoy, Vicki G Davis, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
JAMA|February 22, 2022
Sublingual Dexmedetomidine as a Potential New Treatment for AgitationJohn K Hsiao
JAMA|June 22, 2026
Stopping Alzheimer Disease: 50 Years of ProgressJohn K Hsiao
Psychiatric Services (Washington, D.C.)|January 10, 2006
Interpreting the results of the CATIE studyJeffrey A Lieberman, John K Hsiao
Convulsive Therapy|January 1, 1987
ECT and Neurological DisordersJohn K. Hsiao, John A. Messenheimer, Dwight L. Evans
Convulsive Therapy|January 1, 1988
Disparate Biochemical Actions of Electroconvulsive Therapy and Antidepressant DrugsMatthew V. Rudorfer, Emile D. Risby, John K. Hsiao, et al.
The American Journal of Psychiatry|March 4, 2006
Barriers to employment for people with schizophreniaRobert Rosenheck, Douglas Leslie, Richard Keefe, et al.
Psychiatric Services (Washington, D.C.)|May 3, 2008
What CATIE found: results from the schizophrenia trialMarvin S Swartz, T Scott Stroup, Joseph P McEvoy, et al.
Schizophrenia Research|November 26, 2008
Results of phase 3 of the CATIE schizophrenia trialT Scott Stroup, Jeffrey A Lieberman, Joseph P McEvoy, et al.
The American Journal of Psychiatry|June 4, 2008
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trialDavid L Sultzer, Sonia M Davis, Pierre N Tariot, et al.
Biological Psychiatry|July 31, 2009
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness studyJonathan M Meyer, Joseph P McEvoy, Vicki G Davis, et al.
Pageof 3